11:30 am–12:30 pm Saturday, September 7

Beyond the Cure: The Children’s Oncology Group Uses Evidence and Clinical Trials to Study Late Effects in Childhood Cancer Survivors (C229)

coglogoChildhood cancer survivors are living longer than ever before, with overall survival rates exceeding 80%. As a result, survivors are living with chronic late health effects related to their curative treatments. Late effects may include second malignancies, endocrinopathies, cardiomyopathy, infertility, pulmonary function deficits, renal/ocular/auditory disorders, neurocognitive deficits, and metabolic syndrome.

Read more...
Speaker:
Eleanor Hendershot, MN BScN RN(EC)
CNE Hours
1
RX Hours
0.17
4:15–5:15 pm Friday, September 6

Shaping the Future with Clinical Trials: Empowered Nurses a Key to their Success (C223)

coglogoIn pediatric oncology, clinical trials are conducted to improve survival rates, understand disease biology, and prevent and/or improve management of treatment-related acute and long-term side effects. The majority of children newly diagnosed with cancer in North America are treated on Children’s Oncology Group (COG) clinical trials. In the last 50 years, clinical trials in pediatric oncology have increased the overall 5-year survival rate from under 10% to over 80% today.

Read more...
11:30 am–12:30 pm Friday, September 6

Livers, Kidneys, and Germ Cells – Oh My! Helping Nurses Understand the Children’s Oncology Group Approach to Unique Childhood Cancers (C217)

coglogoLiver, kidney (renal cell carcinoma), and germ cell tumors are rare cancer diagnoses in children and adolescents (Ward E., et al 2014). Enrollment on clinical trials is essential for the continued improvements in outcomes for children with cancer; however, uncommon childhood malignancies make the conduct of these trials a significant challenge (Czauderna P., et al 2016).

Read more...
5:00–6:00 pm Thursday, September 5

Infant ALL: Rearranged for the Big Screen! Providing Care on COG AALL15P1, Nurses in a Leading Role! (C211)

coglogoAcute lymphoblastic leukemia (ALL) is the most common pediatric malignancy, with 5-year overall survival rates exceeding 90% (Hunger, Lu, Devidas, Camitta, Gaynon, Winick, 2012). Unfortunately, infants with ALL are an exception to the improving survival trends and remain one of the most challenging populations in pediatric hematology/oncology (Kotecha, Gottardo, Kees, Cole, 2014).

Read more...
3:45–4:45 pm Thursday, September 5

Navigating 131I-MIBG and CAR T 19, in COG trials ANBL1531 and AALL1721: Sharing Care and Strategies for Success (C205)

coglogoThe Children’s Oncology Group (COG) is committed to improving outcomes for pediatric oncology patients with the high-risk disease through clinical trials. Despite tremendous advancements in pediatric oncology treatment, survival in two patient populations remains inferior. Patients with high-risk neuroblastoma have a projected 3-year event-free survival of 73% (Park et al., 2016), and patients with precursor B lineage acute lymphoblastic leukemia with positive minimal residual disease at the end of consolidation have a projected 5-year disease-free survival of 39% (Borowitz et al., 2015).

Read more...
2:15–3:15 pm Saturday, September 7

Get Out of Here! Surgical Resection of Solid Tumors in Pediatric Patients (232)

The purpose of this session is to educate our audience on 3 types of solid abdominal tumors and show how surgery is pivotal to increasing survival and decreasing the amount of systemic therapy needed. As APHON nurses, we frequently educate ourselves on chemotherapy, radiation therapy, and immunotherapy. The role of surgery is crucial to the treatment and survival of pediatric oncology patients.

Read more...
2:15–3:15 pm Saturday, September 7

A New Tool for Documenting the Child's Report of Cancer Treatment Toxicity (230)

The National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE) is the standard lexicon for grading adverse events (AEs) in oncology trials. Children with cancer experience significant numbers of subjective AEs such as fatigue, pain, or sadness. The current standard is that AEs are reported only by clinicians, even though 30% of the 790 CTCAE items are subjective.

Read more...
11:30 am–12:30 pm Saturday, September 7

Creating the Spark - Inspire Learning with Interactive Activities for the Chemotherapy/Biotherapy Provider Course (226)

The 4th edition of the APHON Chemotherapy and Biotherapy Curriculum was published earlier this year. Extensive updates to the 4th edition book and live instructor course created a need to provide ongoing support for the 550 instructors as they familiarize themselves with the updated content and revised lectures. Central to the updated material is a focus on interactive teaching strategies.

Read more...
11:30 am–12:30 pm Saturday, September 7

Diagnostic Dilemmas in Pediatric Oncology Patients with Rare Neurological Complications: A Complex Case Series Review (224)

Advanced Care Providers (ACPs) are experts at treating common conditions that children with cancer experience; however, unusual clinical presentations can create a diagnostic dilemma with subsequent difficulty in management. When a challenging diagnostic case is faced in clinical practice, or when a patient does not respond to first-line interventions for a complication, the ACP must be equipped to identify differential diagnoses and understand the appropriate evaluations. This presentation will review four children with cancer who had atypical neurologic complications or manifestations.

Read more...
4:15–5:15 pm Friday, September 6

Immune-Mediated Thrombocytopenia: An Overview (221)

Immune-mediated thrombocytopenia, or “ITP,” is one of the most common causes of symptomatic thrombocytopenia in children and adolescents. Clinical presentation and course, epidemiology, diagnostic modalities and criteria, treatment options, and long-term sequelae will be reviewed with attention to the nurse/advanced practice nurse who desires a comprehensive overview of the subject. Case studies will be utilized to highlight the frequent clinical variance of the condition. Read more...
Subscribe to this RSS feed